If you're offered a thymosin alpha-1 prescription, use this checklist.

A real substance, with a separate question about benefit

A peptide joins together the small building blocks found in proteins. Thymosin alpha-1 was first found in the thymus, a gland in the chest that helps the body's defenses develop.

The manufactured version has another name: thymalfasin. Researchers think it changes how some cells in the body's defenses act, but its exact action in people remains unsettled.

Immune system means the defenses the body uses against illness. A claim about how a substance affects those defenses does not, by itself, show that it helps a person feel or get better.

Italy's approval does not apply in the US

Italy had authorized thymalfasin (Zadaxin) as a prescription medicine as of September 28, 2026. The use described by regulators is an addition to flu vaccination for people with weakened immune systems.

That Italian authorization does not grant permission to market it in the US; the US position recorded on September 28, 2026 remained no FDA approval.

When an offer says it is approved, ask which country, which product and which use the statement refers to.

What compounding means here

Compounding is when a pharmacist or doctor prepares a medicine rather than supplying a finished drug from a manufacturer.

The FDA does not review a pharmacy-made medicine's quality, likely benefit or possible harm before it is sold. This was the position recorded on September 26, 2026.

The raw ingredient is a separate check

Federal ingredient rules for ordinary compounding pharmacies were checked on September 26, 2026. A raw ingredient must meet an official written quality standard, if one exists. Without that standard, it must be part of an FDA-approved drug or be on the FDA's allowed list. A prescription alone does not satisfy these requirements.

The record checked September 28, 2026 found no official written quality standard for thymosin alpha-1 as a raw ingredient. It was also missing from the allowed list and was not part of any FDA-approved drug.

A prescription did not make that raw ingredient lawful for an ordinary pharmacy to use under the September 28, 2026 rules.

Ask the doctor and pharmacy which rule lets them offer this treatment.

Taking back a request did not allow pharmacy use

People had asked the FDA to add thymosin alpha-1 to the list of raw ingredients ordinary pharmacies can use. Those people later took their requests back. The FDA page updated April 22, 2026 lists those requests as withdrawn and still warns about possible reactions from the body's defenses.

Under a temporary FDA policy checked September 26, 2026, the agency does not plan to act against pharmacies using certain listed ingredients if its conditions are met. This describes when the FDA plans to take action, rather than giving legal permission.

Thymosin alpha-1 was outside that temporary policy at the September 28, 2026 check. Taking back the request did not allow an ordinary pharmacy to use the raw ingredient.

A panel's advice is not a final rule

In December 2024, an FDA advisory panel voted against adding either form of the ingredient to the allowed list. Such a panel advises the agency; its vote does not change the law.

The federal record checked September 28, 2026 showed no final FDA rule deciding whether to add thymosin alpha-1 to the allowed list.

The unfinished decision did not remove the existing ingredient rule. Without a quality standard, a place in an approved drug or an entry on the allowed list, this raw ingredient still failed that rule.

A long research history is not a clear treatment result

The FDA's review in 2024 found insufficient evidence of benefit for every use it evaluated. Those uses included cancer, serious infections and helping vaccines work better.

That is a limit on what the evidence supports. It is not proof that the substance can never help anyone.

Fatigue needs its own answer

The FDA's 2024 review found no studies testing thymosin alpha-1 in people with chronic fatigue syndrome. Research on other illnesses cannot answer whether it helps people with that illness.

Bring the symptom that led to the search into the conversation. Ask the doctor to consider other causes and discuss other ways to care for the problem.

Look past an encouraging headline

A review published in 2023 did not find a lower death rate with thymosin alpha-1 among adults hospitalised with COVID-19.

For a paper mentioned in an offer, ask who took part, what the researchers measured and whether the result fits your own problem. A study title is a place to begin reading, not the answer.

Choose the setting around the assessment

An in-person clinic gives you a room for the conversation. Telehealth means having it by video, phone or an online exchange. Neither setting answers the ingredient or evidence questions on its own.

Ask a licensed doctor to review the health concern behind your request, the other options and the reason for any proposed treatment.

Leave space for follow-up online

A national group representing the state bodies that oversee doctors publishes advice about online care. This advice is not itself state law. Treatment cannot rest solely on a fixed form that leaves the doctor unable to ask further questions, says the guidance checked September 26, 2026.

Your state's own law sets the requirements for doctors. A form that lets a doctor ask for more information differs from one that only accepts a fixed set of answers.

The medical boards' advice also calls on the doctor to arrange tests or an examination in the same room if online care cannot complete the assessment.

Check the people doing the work

A doctor's state permission must cover the place where the patient is during the visit, according to guidance checked September 26, 2026. A doctor needs the relevant license or other state authorization; narrow exceptions depend on state rules.

A state medical board licenses and disciplines doctors. Ask for the doctor's full name, then check that board's public record for the license and any disciplinary action.

Ask which pharmacy would prepare and dispense any medicine. Use the FDA's state-by-state links to look up the pharmacy's license. A record proves licensed status, not that a given treatment offer is appropriate.

Bring the question behind the request

Write down what has been bothering you, what you hope might change and what care you have tried. Bring your current medicines and health history into the discussion.

Ask how a benefit would be judged, who would review progress and whom to contact with a concern. A useful visit may end with a different plan from the one you had in mind.

There is no US list price to anchor an offer

As recorded on September 28, 2026, no US manufacturer's list price or government price was available for thymosin alpha-1 because there was no approved US product.

A clinic's quote tells you what that clinic plans to charge. It is not a price for an FDA-approved thymosin alpha-1 medicine; no such US product existed at the September 28, 2026 check.

Ask for a full written quote

Ask whether the quoted total includes the care visit, any membership, medicine, tests, delivery and future reviews. Request a separate amount for each item that applies.

For a plan with an opening discount, ask for the charge after the discount ends and the terms for cancellation. Compare quotes that cover the same things.

Find out what happens if treatment does not go ahead

Ask which fees you still owe if the doctor decides against treatment. Ask when any repeated charge begins and which fees can be returned to you.

Give your insurance plan the exact service and medicine named in the quote. Ask for a written answer stating what the insurer will pay and what you will still owe.

A code or badge is not product approval

Under the federal rule checked on September 26, 2026, registering a business or listing a drug with the FDA does not confer approval. An NDC, the identifying code in the government's drug directory, is not proof of approval either.

Ask for the record behind an approval claim. A seal on a page is not the record.

A research label does not create a care route

In enforcement letters reviewed September 26, 2026, the FDA said research-only labels did not excuse products marketed for human use. The label did not remove the drug rules.

Do not treat a research-labelled product as a substitute for a medical assessment.

Study reports do not clear a pharmacy product

In the studies reviewed by the FDA in 2024, common reported problems included redness, irritation and discomfort around the injection site. Those reports concerned study products and supervised care; they do not establish the safety of a pharmacy-made product.

The FDA's 2024 reviewers also raised concern about clumped peptide and impurities causing an immune reaction. In plain words, the body's defenses may treat the injected material as an invader.

Personal history belongs in the visit

The FDA's 2024 summary of Italy's Zadaxin label says the medicine must not be used during pregnancy or breastfeeding. The label calls for caution in people prone to allergies or with a past allergic reaction. It also calls for caution when other medicines act on the body's defenses.

Discuss these label warnings with a doctor; they are not enough to decide for yourself whether treatment is suitable. Tell the doctor about transplant care or medicines that deliberately reduce the body's defenses.

Bring your medicine list so the doctor can check which medicines affect the body's defenses.

Get help for a sudden severe reaction

A severe allergic reaction may involve a swollen tongue or face, or breathing that becomes difficult. Get emergency help at once if these symptoms occur.

Find a term or a word in its meaning

All terms are shown.